Therapeutic D-peptide Inhibitor of HIV entry

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43AI095172-01A1
Agency Tracking Number: R43AI095172
Amount: $299,392.00
Phase: Phase I
Program: SBIR
Awards Year: 2011
Solicitation Year: 2011
Solicitation Topic Code: NIAID
Solicitation Number: PA10-050
Small Business Information
383 Colorow Drive, SALT LAKE CITY, UT, -
DUNS: 792046224
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 (801) 587-1426
Business Contact
Phone: (801) 990-2498
Research Institution
DESCRIPTION (provided by applicant): HIV/AIDS remains a formidable global epidemic with 33 million infections worldwide, including over 1 million patients in the US. In 2008, there were 2.7 million new infections and 2 million AIDS-related deaths. CurrentHIV treatment combines drugs from several classes of HIV inhibitors and has dramatically extended the lives of many HIV patients, but serious side effects and rapidly increasing drug resistance are significant concerns. Thus, there is a continuing need todevelop HIV inhibitors with new mechanisms of action and more robust resistance profiles. Navigen Pharmaceuticals is a pharmaceutical development company targeting infectious diseases. Using a combination of discovery and design, we have identified a novel type of HIV entry inhibitor (protease-resistant D-peptide) that targets HIV's conserved extracellular entry machinery and overcomes the limitations of existing HIV entry inhibitors (e.g., frequent and high dosing, narrow breadth, injection site reactions, and susceptibility to resistance). Our lead prototype (PIE12-trimer) potently inhibits diverse strains from all major subtypes of HIV and is extraordinarily elusive to resistance. We have developed multiple variants of PIE12-trimer in an effort to minimize dosing frequency and have selected two that we expect to be superior. In this one-year grant application, Navigen proposes to (1) develop a bioanalytical assay to support preclinical development of PIE12-trimer, (2) measure pharmacokinetic (PK) properties, and (3) conduct acute, 7-day, and 28-day rat toxicity studies on the two most promising lead candidates. This information will allow Navigen to select an ideal PIE12-trimer variant with low toxicity and PK properties compatible with weekly dosing for advancement into IND-enabling studies and ultimately clinical trials. PUBLIC HEALTH RELEVANCE: Navigen Pharmaceuticals is developing a potent and novel inhibitor of HIV entry. The goal of this study is to optimize our lead candidate for weekly dosingand low toxicity. If successful, this new inhibitor will improve the health of HIV/AIDS patients by providing them with a safe and highly effective new therapeutic option.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government